317 results on '"Feagan, B. G."'
Search Results
52. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohnʼs disease
53. OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
54. OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 study
55. A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
56. A17 EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
57. Review article: a clinicianʼs guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
58. Evaluation of a daily practice composite score for the assessment of Crohnʼs disease: the treatment impact of certolizumab pegol
59. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab
60. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohnʼs disease in the PRECiSE 2 study
61. Medical management of mild to moderate Crohnʼs disease: evidence-based treatment algorithms for induction and maintenance of remission
62. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
63. CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohnʼs disease: a randomized, double-blind, placebo-controlled trial
64. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohnʼs disease
65. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
66. Mild to moderate Crohnʼs disease – defining the basis for a new treatment algorithm
67. Systematic review: the effectiveness of budesonide therapy for Crohnʼs disease
68. Transfusion practice in elective orthopaedic surgery
69. Review article: economic issues in Crohn's disease - assessing the effects of new treatments on health-related quality of life
70. P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment
71. P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis
72. P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
73. OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study
74. A130 SAFETY OF COMBINATION BIOLOGIC AND ANTI-REJECTION THERAPY POST-LIVER TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: LONDON ONTARIO EXPERIENCE
75. A145 ORAL 5-ASA FOR INDUCTION AND MAINTENANCE OF REMISSION IN ULCERATIVE COLITIS
76. A96 ADALIMUMAB FOR MAINTENANCE OF REMISSION IN CROHN’S DISEASE
77. Review article: Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy
78. A Randomized Study Comparing Patient-Directed Hypertension Management with Usual Office-Based Care: PIII-58
79. Oral Budesonide is Effective In Active Crohnʼs Disease
80. P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial
81. DOP39 Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience
82. P373 Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn’s disease: Phase 2 trial results
83. P687 Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial
84. P315 Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease
85. P631 Development and validation of a clinical scoring tool for predicting treatment outcomes with vedolizumab in patients with ulcerative colitis
86. DOP71 Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis
87. DOP79 Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials
88. OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study
89. An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease
90. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease
91. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
92. Editorial: validating reliability of the eosinophilic oesophagitis histological scoring system (EOE-HSS)-an important first step. Authors’ reply
93. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis
94. Reliability of histologic assessment in patients with eosinophilic oesophagitis
95. A114 SYSTEMATIC REVIEW AND META-ANALYSIS: ENDOSCOPIC AND HISTOLOGIC PLACEBO RATES IN INDUCTION AND MAINTENANCE TRIALS OF ULCERATIVE COLITIS
96. A80 ENDOSCOPIC HEALING WITH USTEKINUMAB IN CROHN’S DISEASE: THE UNITI ENDOSCOPY SUB-STUDY
97. A333 THE ROLE OF IMAGING IN DETERMINING PROGNOSIS FOR PRIMARY SCLEROSING CHOLANGITIS: A SYSTEMATIC REVIEW
98. A92 ANTIBIOTICS FOR INDUCTION AND MAINTENANCE OF REMISSION IN CROHN’S DISEASE
99. A111 INFLIXIMAB FOR INDUCTION OF REMISSION IN CROHN’S DISEASE
100. A102 TOLERABILITY OF USTEKINUMAB IN INDUCTION AND MAINTENANCE FOR THE TREATMENT OF CROHN’S DISEASE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.